A) Small interfering RNA strands B) Cationic polymers mixed with mRNA C) Natural ribonucleases D) Lipid-based microfluidic mixers
A) Scaling up microfluidic production B) Targeting only the lymphatic system C) Creating ionizable cationic lipids D) Protecting mRNA from ribonucleases
A) Polymer vector B) Lipid nanoparticle C) Onpattro D) Protamine
A) Onpattro B) COVID-19 mRNA vaccine C) Polyplex coating D) Protamine encapsulation
A) 2015 B) 2018 C) 2020 D) 2022
A) mRNA strands are much longer than siRNA B) siRNA lipids are non-cationic C) Lipids for siRNA were too expensive D) mRNA requires higher temperatures
A) Replacing the need for microfluidics B) Protection against degradation C) Increasing mRNA strand length D) Reducing cellular intake
A) Changing the internal mRNA length B) Adjusting the patient's lymphatic flow C) Using different ribonuclease enzymes D) Customizing the lipid's outer layer with ligands
A) Inconsistency between in vivo and in vitro applications B) Lack of protective lipid layers C) High cost of producing mRNA strands D) Inability to administer intravenously
A) Encapsulation in siRNA B) Oral ingestion of polymers C) Intravenously D) Direct ribonuclease injection
A) Ribonuclease synthesis B) Massive parallel pipetting C) Direct polymer mixing D) Microfluidics
A) The lipids are incompatible with microchannels B) They require high temperatures to function C) They consume too much electricity D) They exploit microscale behaviors of liquids
A) Running many microfluidic chambers in parallel B) Eliminating the need for reaction chambers C) Replacing lipids with cationic polymers D) Developing larger microfluidic mixers
A) FDA approval delays B) Synthesizing mRNA strands C) Scaling microfluidic reaction chambers D) Protamine availability
A) Natural protamine lipids B) Polyplex-derived lipids C) Ionizable cationic lipids D) Standard ribonuclease lipids
A) Micro-milligrams B) Liter quantities only C) Grams or kilograms D) Several tons
A) Introns B) Double-stranded DNA C) Histone proteins D) 3'-poly(A) tail
A) 5'-untranslated region B) 5'-cap C) 3'-untranslated region D) Open reading frame
A) Increasing RNAase concentration B) Reducing the length of the UTR C) Modifying structural components D) Removing the 5' cap
A) Decreased innate immune activation B) Decreased mRNA half-life C) Increased RNAase sensitivity D) Loss of the poly(A) tail
A) Enhanced protein production B) Reduced mRNA translation C) Increased mutation rate D) Inhibition of the open reading frame
A) Electrostatic repulsion B) It is positively charged C) It is too small D) It lacks a poly(A) tail
A) Proteases B) T7 polymerase C) DNA polymerase D) RNAases
A) T7 phage protein fragments B) In vivo transcription in blood C) Natural eukaryotic ribosomes D) Engineered plasmid DNA
A) It is too small B) It is too large C) It lacks a 5' cap D) It is not negatively charged
A) 2010 B) 2005 C) 2008 D) 2001
A) Modified nucleosides B) Viral vector delivery C) Dendritic cell transfection D) Lipid nanoparticle encapsulation
A) 2008 B) 2013 C) 2010 D) 2001
A) Moderna B) BioNTech C) AstraZeneca D) Pfizer
A) Merck B) Moderna C) GSK D) BioNTech
A) RAPID B) VACCINE C) DEFEND D) ADEPT
A) $50 million B) $10 million C) $25 million D) $100 million
A) 2015 B) 2013 C) 2010 D) 2008
A) Rabies B) Chikungunya virus C) Zika virus D) Influenza
A) Ebola B) HIV C) Chikungunya virus D) Smallpox
A) To store energy B) To replicate the cell's DNA C) To destroy lipid nanoparticles D) To build foreign proteins
A) Antibodies B) Lipid nanoparticles C) Protein capsules D) Cellular enzymes
A) The method of storage B) The cost of production C) The tendency to produce adverse reactions D) The speed of immune response
A) People with high blood pressure B) People with viral infections C) People who are allergic to peanuts D) People susceptible to autoimmune responses
A) US FDA B) UK MHRA C) World Health Organization D) European Medicines Agency
A) 1995 B) 2020 C) 1993 D) 1989
A) Red blood cells B) T cells C) Platelets D) DNA strands
A) Only in cancer cells B) No C) Only in viral cells D) Yes, always
A) December 2021 B) May 2021 C) December 2020 D) January 2020
A) BNT162b2 B) mFlusiva C) mCombriax D) mResvia
A) Dendritic cells B) Ribosomes C) Antigens D) Pathogens
A) Inside the ribosome B) Outside the body C) By the dendritic cells directly D) Inside the cell nucleus
A) mCombriax B) BNT162b2 C) mFlusiva D) mResvia
A) Proteasomes B) Ribosomes C) Genomic DNA D) MHC molecules
A) Proteasomes B) MHC molecules C) Ribosomes D) Dendritic cells
A) Antibodies B) MHC molecules C) Proteasomes D) Ribosomes
A) Liver B) Cell nucleus C) Lymph nodes D) Bloodstream
A) August 2026 B) May 2024 C) February 2026 D) December 2020
A) They are never degraded B) Several months C) A few days D) Several years
A) Viral transduction B) Electroporation C) Liposomal fusion D) Endocytosis
A) Centrifugation B) Osmosis C) Electroporation D) Incubation
A) A nutritional deficiency B) A surgical procedure C) A secondary immune response D) A regular infection
A) 1990s B) 1970s C) 2000s D) 2010s
A) Non-existent B) Delayed by several years C) Extremely potent D) Relatively weak
A) Intranasal sprays B) Intradermal injections C) Intravenous drips D) Intramuscular injections
A) Coronaviruses B) Poxviruses C) Adenoviruses D) Retroviruses
A) Nucleus B) Golgi apparatus C) Cytosol D) Mitochondria
A) Decreased stability B) Faster degradation C) Increased translation D) Integration into the genome
A) Rats B) Chicken C) Dogs D) Sheep
A) Molecular cloning B) Rigorous quality control C) Sequence engineering D) Lipid encapsulation
A) Pseudouridines B) Thymine-pseudouridine C) Guanine-uracil D) Cytosine-adenosine
A) Five B) One C) Zero D) Ten
A) Two weeks B) Eight weeks C) One year D) Six months
A) Any fever above 100 degrees B) Side effects requiring hospitalization C) Any reaction lasting longer than a week D) Those that prevent daily activity
A) Around 50 percent B) Over 90 percent C) Less than 80 percent D) Exactly 75 percent
A) Four B) Three C) Two D) One
A) The cell's internal replication B) The number of open reading frames C) The amount delivered by the vaccine D) The RNA-dependent RNA polymerase
A) One B) Zero C) Two D) Three
A) Lipid nanoparticles B) N1-Methylpseudouridine C) RNA-dependent RNA polymerase D) The antigen of interest
A) Pfizer B) Gemcovac C) ARCT-154 D) Moderna
A) June 2022 B) January 2020 C) November 2023 D) June 2021
A) GSK B) Meiji Seika Pharma C) Gritstone bio D) Arcturus Therapeutics
A) June 2022 B) January 2021 C) November 2023 D) December 2020
A) N1-Methylpseudouridine B) Uridine C) Adjuvants D) DNA polymerase
A) Ebola B) Tuberculosis C) Malaria D) Influenza
A) 2021 B) 2019 C) 2022 D) 2023 |